

# Densitas Inc. mammogram analysis software approved in Europe, Canada

THE CHRONICLE HERALD

Published December 3, 2015 - 10:38am



Densitas CEO Mohamed Abdoell says the firm's DM-Density software has received regulatory approval in Canada and Europe. (TIM KROCHAK / Staff)

A Halifax company got the green light from regulators in Europe and Canada for software it developed to improve screening for breast cancer.

**Densitas Inc.** says it has received both a medical device licence from Health Canada and the CE Mark from the European Commission for its flagship product, DM-Density.

"It's exciting to have DM-Density entering markets with such great potential for sales," Mohamed Abdoell, the firm's CEO and a professor at Dalhousie University, said in a news release issued this week.

"Our products will address the real clinical challenges in the mammography enterprise, focusing on key value pathways that lead to improved care for women."

The company's first commercial software technology, DM-Density, provides precise and consistent breast density measurements from digital images taken during mammograms.

Founded in 2011, the firm earned International Organization for Standardization certification earlier this year and is working on U.S. regulatory clearances for the product.

Company representatives are in Chicago this week for the Radiological Society of North America's annual meeting and presented the technology earlier this year at the European Congress of Radiology in Vienna.

The European appearance generated interest in the product, and company spokeswoman Adele MacLean told TheChronicleHerald.ca in October the firm hoped the U.S. conference would produce a similar response.